Read ASGCT's 2023 Q3 Landscape Analysis Field Report

October 18, 2023

In Q3, a CAR T-cell therapy was approved for multiple myeloma in China and an mRNA vaccine was approved for COVID-19 in Japan.

The third quarterly report of 2023 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Highlights from this issue include:

  • An anti-BCMA-targeting CAR T-cell therapy, Fucaso, was approved for multiple myeloma in China

  • An mRNA vaccine, Daichirona, was approved for COVID-19 in Japan

  • For the first time in more than a year, COVID-19 complications is no longer in the top three specified indications for non-genetically modified cell therapy development

Download the full report


Click any of the samples below to view the full report: